Ticarcilline (Sodique), Acide Clavulanique shortage — FR supply status & alternatives

Ticarcilline (Sodique), Acide Clavulanique

—

In supply · Australia

Claventin

In supply · 🇦🇺 Australia · short in🇫🇷 FR

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Brand names
Active ingredient (INN)	Ticarcilline (Sodique), Acide Clavulanique

Therapeutic category	Auto-created by Agence nationale de sécurité du médicament — Disponibilité scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇫🇷

France

ANSM · just now

High

Recalls official enforcement reports

🇺🇸

Ticarcillin Sodium/Potassium Clavulanate (30:1) Active Pharm

Attix Pharmaceuticals · Nov 2014

Class IIdetails ↗

Verified timeline regulator events

🇫🇷 14 Apr 2026

high reported

🇫🇷 6 Aug 2024

high reported

Sources official regulators

🇫🇷

ANSM

verified just now

verify ↗

Mederti Drug Report

Generated 5 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.